BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38407352)

  • 1. Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
    Nakazawa M; Harada G; Ghanem P; Bubie A; Kiedrowski LA; Murray JC; Marrone KA; Scott SC; Houseknecht S; Falcon CJ; Evans P; Feliciano J; Hann CL; Ettinger DS; Smith KN; Anagnostou V; Forde PM; Brahmer JR; Levy B; Drilon A; Lam VK
    Cancer Res Commun; 2024 Mar; 4(3):786-795. PubMed ID: 38407352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Zhang SS; Nagasaka M; Zhu VW; Ou SI
    Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a highly lethal V3
    Christopoulos P; Kirchner M; Bozorgmehr F; Endris V; Elsayed M; Budczies J; Ristau J; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Lasitschka F; Bischoff H; Sotillo R; Schirmacher P; Thomas M; Stenzinger A
    Int J Cancer; 2019 Jan; 144(1):190-199. PubMed ID: 30255938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
    Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
    Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
    ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
    Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency, clinical features and differential response to therapy of concurrent
    Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
    Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
    Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
    J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged Disease Control Despite ALK Inhibitor Discontinuation in Advanced ALK-Positive NSCLC.
    Hussain SA; Faisal H; Dy GK
    Eur J Case Rep Intern Med; 2024; 11(6):004527. PubMed ID: 38846658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK
    Christopoulos P; Endris V; Bozorgmehr F; Elsayed M; Kirchner M; Ristau J; Buchhalter I; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Warth A; Bischoff H; Schirmacher P; Stenzinger A; Thomas M
    Int J Cancer; 2018 Jun; 142(12):2589-2598. PubMed ID: 29363116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.
    Christopoulos P; Dietz S; Angeles AK; Rheinheimer S; Kazdal D; Volckmar AL; Janke F; Endris V; Meister M; Kriegsmann M; Zemojtel T; Reck M; Stenzinger A; Thomas M; Sültmann H
    Transl Lung Cancer Res; 2021 May; 10(5):2118-2131. PubMed ID: 34164264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
    Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
    Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
    Liu C; Liu C; Liao J; Yin JC; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Shao Y; Wang J
    Lung Cancer; 2022 Sep; 171():18-25. PubMed ID: 35870258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC.
    Lara-Mejía L; Cardona AF; Mas L; Martin C; Samtani S; Corrales L; Cruz-Rico G; Remon J; Galvez-Nino M; Ruiz R; Rios-Garcia E; Tejada F; Lozano-Vazquez N; Rosell R; Arrieta O
    J Thorac Oncol; 2024 Jan; 19(1):119-129. PubMed ID: 37572870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (
    Li J; Huang K; Ji H; Qian J; Lu H; Zhang Y; Russo A; Romero A; Urbanska EM; Tabbò F; Zhao X; Chu T
    Transl Lung Cancer Res; 2023 Dec; 12(12):2505-2519. PubMed ID: 38205204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.